Shire secures $5 billion funding for NPS Pharma bid: The Times
(Reuters) - London-listed drugmaker Shire Plc has secured a $5 billion credit facility for a takeover offer for New-Jersey-based NPS Pharmaceuticals, The Times of London reported on Sunday.
The newspaper said Shire has lined the credit facility for NPS, which is being advised by Goldman Sachs, from banks led by Citigroup. (link.reuters.com/kuk79v)
Insiders told The Times that an initial approach to NPS by Shire has been rebuffed. However, a former London hospital doctor with ties to both companies is acting as a go-between, the daily said.
The Times reported that Colin Broom, who is on the board of NPS and the chief scientific officer of U.S. company ViroPharma that was taken over by Shire last year, would be a key figure in the takeover talks.
The Financial Times blog, Alphaville, was the first to report on Shire considering a bid for NPS Pharma on Friday.
Shire could not be contacted for comment outside of normal business hours.
NEW YORK - A deal to resolve a U.S. regulator's claims against Goldman Sachs Group Inc over mortgage-backed securities sold to Fannie Mae and Freddie Mac leading up to the financial crisis could cost the bank between $800 million and $1.25 billion, according to a person familiar with the matter.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.